Enzyme-linked immunosorbent assay (ELISA) is often used to test bovine leukemia virus (BLV) infection. However, commercially available kits test in South America detect only antibodies against the gp51 protein. With the aim to improve the sensitivity of the test, we developed here a two-step indirect dual ELISA test that included both proteins p24 and gp51, expressed and produced in E. coli and baculovirus expression system respectively. Two hundred ten BLV sera, stated as double positive or double negative by the combination of commercial agar gel immunodiffusion (AGID) assay and a gp51-ELISA test, were tested with our in house dual rp24/rgp51 ELISA. Firstly, we checked the purified, optimized and standardized proteins as antigen by the checkerboard technique, and set up our in house ELISA test. The concordance correlation coefficient (CCC) and coefficient of variation (CV) intraplate repeatability levels were within the values established by the international standards. The statistical analysis demonstrated the value of sera correctly ranked highest (93.48%), and for 0.3 cutoff, the sensitivity was 95.65% and the specificity 91.30%. In conclusion, the rp24/rgp51 ELISA developed and standardized here demonstrated to have good analytical characteristics to be considered for screening of BLV.
Introduction
The bovine leukemia virus (BLV) is the causative agent of Enzootic Bovine Leukosis (EBL), a lymphoproliferative type disease that affects B cells, and the provirus is integrated into the genome, transforming infected animals in Lifetime carriers [1] . Given the multiple transmission routes, both natural and iatrogenic and the minimum volumes of peripheral blood required to transmit the virus, this disease has a high potential for disease transmission [2] [3] .
The economic impact of this disease lies not only in direct losses for confiscation at the slaughterhouse, but also the associated carrier status of the animal, with an important decrease in animal productivity [4] ; that also include the costs of veterinary services, diagnosis and treatment of the disease, as well as the costs of early animal replacement [5] .
The Bovine leukemia virus (BLV) is an exogenous B-lymphotropic retrovirus that naturally provokes B-lymphoproliferative disorders in cattle and can be used to induce a related B-cell-associated pathology in experimentally infected sheep [6] . Structural proteins p24 and gp51 are potent immunogens and the antibody production can be detected in most of the animals infected with VLB. In experimentally infected animals anti-gp51 antibodies seem to be the first to appear with titres consistently higher than anti-p24 antibodies [7] [8] [9] . Other authors reports that high sensitivity tests are able to detect anti-p24 antibodies before the appearance of anti-gp51 antibodies; and the anti-p24 antibodies could be an equal or greater degree than anti-gp51 [3] [10] . The immunoglobulin isotype in the immune response varies according to the stages of LEB disease, in asymptomatic animals IgM and IgG1 anti p24 and gp51were detected, whereas the detection of IgA occurs in animals with lymphoma [11] .
The most frequently used serological tests to detect VLB infection are agar gel immunodiffusion (AGID) and enzyme-linked immunosorbent assay (ELISA).
The AGID, that mainly detects anti-gp51 antibodies [9] , is a test with high specificity, low cost, quick and easy to perform, but with some main disadvantages like low sensitivity, time consuming for reading and subjective interpretation of test results and is unable to be performed with milk samples [12] . At the present, the detection of specific antibodies based on the recognition of crude antigens by AGID or ELISA requires mass production of the virus from persistently infected FLK cell lines cultures. The use of Escherichia coli or baculovirus expression systems to produce recombinant antigen(s) would be greatly beneficial in improving standardization of the tests and reducing their production cost.
Enzyme-linked immunosorbent assay (ELISA) tests using VLB antigens have already been reported [12] [13] , but compared to the current serological tests, none of these recombinant antigens has allowed detection of all serologically positive individuals. The aim of this study was to develop an indirect dual ELISA test that included both recombinant proteins p24 and gp51 directly absorb to the 96-well plate, to be used in Argentina and other countries of South America. The use and evaluation of the two recombinant antigens could be a strategy to improve the sensitivity of recombinant antigen-based tests for the serodiagnosis of LEB.
Materials and Methods

Sera Samples
A total of 283 serum samples, collected from naturally infected adult cows from different herds, were obtained from the serum bank of the Virology Laboratory of the Veterinary Faculty of University of La Plata, Argentina. The sera samples were tested for the presence of BLV specific antibodies by AGID and a commercial indirect ELISA test. International reference serum sample E4 (Veterinary Laboratories Agency. New Haw, Adelestope Surrey. UK) was used as control.
Recombinant Antigens Production
Expression and Purification of Recombinant p24 Antigen in
Bacterial Cell The complete coding region for the p24 gene of the BLV was amplified by PCR using the FLK (fetal lamb kidney) BLV infected cell line as a template. The primers used carried a Bam HI restriction sites for the forward primer (5'-GGC GGA TCC ATG CCA ATC ATA TCT GAA-3') and a Hind III site for reverse primer (5'-GGC AAG CTT TAG AGA AGT GCA GGC TGT-3'). The primers were designed based on the genomic sequence deposited in GenBank under accession number K02120.1. PCR was carried out by denaturing at 94˚C for 2 minutes, 30 cycles of: annealing at 50˚C for 45 seconds, extension at 72˚C for 2 minutes, followed by a final extension period at 72˚C for 10 minutes. The PCR product was digested with both BamHI and HindIII, cloned into the pQE-30 expression vector (QIAGEN)) and the transformation of competent M15
[pREP4] E. coli cells (QIAGEN) were performed according to the manufacturer's instructions. To determine the presence of the recombinant plasmid, a PCR was performed and the product was used for confirm the insertion of the gene in frame. The absence of mutations in the p24 gene was confirmed by plasmids sequencing using M13 forward and reverse primers. The sequencing results were analyzed by comparing with databases and using the basic local alignment search tool (BLAST) software.
The selected E. coli p24/clones were inoculated into LB medium contained 0.1 mM of IPTG (isopropyl-bD-thiogalactopyranoside) for induction; the medium was supplemented with ampicillin (100 mg/ml) and kanamycin (25 µg/ml). The purification of the recombinant protein was performed in batch, the buffer used (50 mM NaH 2 PO 4 and 500 mM NaCl), was the same all along the protocol. The cells were pelleted and resuspended in lysis buffer pH7, lysozyme (1 mg/ml) was added and incubate at 37˚C for 30 min. The lysis was completed by few rounds of sonication. The presence of the protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using a 12% polyacrylamide gel and the antigenicity of the protein by Western blot analysis according to the standard proceeding, using E4 control sera (Veterinary Laboratories Agency. New Haw, Adelestope Surrey. UK), a commercial BLV p24 monoclonal antibody (VMRD Inc., WA USA) and a pool of negative control serums.
The recombinant protein were purified from the supernatant lysate using Ni-NTA (QIAGEN, USA) and eluted off the resin by buffer pH4.The concentration of the recombinant protein was determined by a quantitative Coomassie blue-stained gel using bovine serum albumin as the standard. 
Expression and Purification of Recombinant gp51 Antigen in Insect Cell
AGID and Commercial gp51-ELISA Tests
The AGID test, produced by Universidad de LaPlata, Argentina (UNLP-AGID) and a commercial indirect ELISA test kit (VMRD Inc., USA) that detect antibodies against BLV gp51 protein, were used according to the manufacturer's recommendations. Both tests were used as standard of comparison against our in house ELISA to detect specific BLV antibodies.
In House rp24/rgp51 ELISA Procedure
Two checkerboard tests (CBT) was performed, one for each individual recombinant protein (rp24 and rgp51) and the third with a mix of the two proteins. The checkerboard results are assessed by determine the Binding Ratio (BR) [14] .
Statistical Analysis
The repeatability within and between plates was analyzed by the reproducibility index called the concordance correlation coefficient (CCC) and coefficient of 
Results
Expression, Purification and Characterization of rp24 in E. coli
The PCR amplification assay generated a unique fragment with the expected molecular level (642 bp) and visible on agarose gel under ultraviolet light (Figure 1(a) ). After cloning of the PCR product to the pQE-30 expression vectorthe present of the gene was confirmed by PCR and the purified selected plasmid, contained the p24 gene in frame, was sequenced. The sequence analyzed by comparing with databases from BLV reference strains showed a 99% of nucleotide identity with BLV cell-line FLK-BLV subclone pBLV913 (GenBankID:
EF600696.1) and 98% of nucleotide identity con BLV (GenBankID: K02120.1) [18] .
The analysis by SDS PAGE of the Denatured lysate of induced E. coli M15 The expressed rp24 protein was subsequently purified using Ni-NTA affinity 
Expression, Purification and Characterization of rgp51 in Baculovirus
The PCR amplification assay generated a unique fragment with the expected molecular level (894 bp) and visible on agarose gel under ultraviolet light (Figure 3(a) ). A consensus Gateway entry clone was used to produce a baculo- 
Serum Control Panel Determination by AGID and ELISA Commercial Kit
Of a total of 283 serum samples analyzed by AGID and commercial ELISA kits, were stated 101 as double positive and 109 as double negative. These serum were selected for further analysis, the 73 serum samples that reacted with discordant results between both assays were not included for the in house ELISA test.
Characteristics Estimation of the in House ELISA Test
The optimal concentration of recombinant proteins used as antigen for the in house ELISA determinate by CBT, were 250 ng per well for rp24 and 25 ng per well for rgp51. Three sera dilution were tested (1/25, 1/50 and 1/100) to determine the optimal performance of the assay, and the 1/25 serum dilution were used to perform the assay according to the best banding ratio value. The software package Stata version 11 calculated the correct classified serum percentage (CC%) and the likelihood ratio for positive sera (LR+), that allow to disclosed the diagnostic sensibility (DSe) and specificity (DSp) of our in house ELISA test showed in the Table 1 .
Discussion
In the epidemiological disease control of EBL it is necessary to have tests that increasingly sensitive, specific and be economically feasible to performed in large populations of animals. During the immune response against BLV the synthesis and persistence of specific anti-p24 and anti-gp51 antibodies is lifelong [9] [19] [20] , this features make these two highly immunogenic proteins as candidate to be included in any diagnostic test for EBL. Firstly, in this study we successfully produced a recombinant p24 protein with a proved antigenicity against the control sera, the bacterial expression system achieved a mass production of approximately 5.6 mg per liter cultures. However, the production of the recombinant gp51 protein was obtaining from the baculovirus expression system. Although the presence and antigenicity of the recombinant gp51 protein in Sf9 insect cells was evident by Western blot analysis, the recombinant protein recognized by the monoclonal anti-gp51 antibody, showed the presence of several protein fractions with molecular weights ranging from 34 kDa to about 50 kDa. All of these proteins or protein fractions that migrated faster than the native gp51 molecules, could represent partially glycosylated recombinant protein. However, the protein were anyway recognized by the positive control serum and the antigenicity maintaining its character despite incomplete glycosylation. Similar finding were reported in previous works by Giusseppe et al. [21] using the baculovirus system. From this data, we can assume that the heavier fraction corresponded to the band located at the height control molecular weight of 35 kDa, suggesting that part of the recombinant protein could be identified as partially glycosylated orunglycosylated product. The antigenic identity of the recombinant gp51 protein was confirmed also by the use of polyclonal control positive sera in western blot analysis. Following production and purification of recombinant gp51 protein in the baculovirus system, a concentration of 0.2 mg was obtained from 5 × 10 7 Sf9 cells.
To develop our in house ELISA test, firstly we checked the purified, optimized and standardized proteins asantigen by the checkerboard technique, in order to determine the concentration of the antigen and the sera dilution to be use in the test. Two independent ELISA tests for rp24 and rgp51 and also the dual ELISA rp24/rgp51 integrated proteins were tested. We tried different brands of 96-well plates and found that the 96-well plates from Nunc-Immuno Plates Polysorb (InterMed, Co. Denmark) were the more appropriate support to perform our in house ELISA test, because were where the recombinant antigens were best adsorbed to the plate. Also, the antigenicity of the joined together recombinant proteins were kept unalterable during the development of the indirect ELISA test.
From the analysis of the checkerboard results, we can concluded that a high BR at a concentration within the parameters suggested by R. Crowther [14] , were obtained using a concentration of 250 ng per well of rp24 and 25 ng per well of rgp51. These antigen concentrations were maintained throughout all the tests. To perform the calculations and analysis of the results, the absorbance values were standardized as percentage of seropositive values.
According to the results presented here (CCC and CV analysis) intraplate repeatability levels were within the values stablished by international standards [22] . Through the experiment, several dual rp24/rgp51 ELISA tests were performed using 3 different sera dilutions (1/100, 1/50 and 1/25), in behalf of that it was possible to improve the performance of the test, achieving significant advances in DSe and DSp attached to the higher percentage of correct classification (predicted probabilities), together with a likelihood ratio of 11.
In order to validate the results of our in house ELISA, we determine the number of samples to be processed according to the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals Table No . IV.2 [22] , where the theoretical number of samples from animals of known infection status required for establishing DSe and DSp estimates depending on likely value of DSe or DSp and desired error margin and confidence.
Given the sensitivity value of 95.65% obtained for the test at 1/25 dilution, we determined the number of samples to be processed with 5% of estimated error and a confidence interval of 90%. In our study, a total of 210 double positive or double negative sera were analyzed. The statistical analysis shows the value of sera correctly ranked highest (93.48%) and for 0.3 cutoff, DSe was 95.65% and DSp 91.30%.
The World Organization for Animal Health (OIE) determines that the tests for the diagnosis of LEB are the Indirect ELISA and AGID. In our country the health authority accepts these two official tests, but so far there is no domestic production of commercial ELISA. The aim of developing a diagnostic test that includes together the two recombinant proteins (gp51 and p24), is to improve the DSe and DSp when the two proteins go together directly absorb to the 96-well-plate.
Considering the prevalence of the disease and its consequences in the reduction of the productivity of livestock and indirect economic losses from the re-striction in international market [4] [23], it is required to developed diagnosis tools that increase sensitive, specific and also be economically feasible to use in large livestock farms.
Conclusion
In conclusion, we developed here a dual rp24/rgp51 ELISA test with two very promising recombinant antigens. This assay is a two-step ELISA which involves two binding process of primary antibody and labeled secondary antibody, without using monoclonal antibodies precoating the plate. Despite a larger number of samples should be analyzed to validate the preliminary data obtained in this study; our ELISA assay has proven to be sensitive and specific, to have a good reproducibility, to be easy to perform, and to be suitable for screening animals for BLV infection. This test could be taken into account as a valid alternative to the AGID, not only in our country but also in others countries of South America.
